What is Critical Diagnostics?
Critical Diagnostics operates at the intersection of biotechnology and clinical cardiology, specializing in the development of novel biomarkers designed to enhance patient outcomes in cardiovascular disease management. The company's core value proposition lies in its ability to provide physicians with actionable data that facilitates early intervention while simultaneously addressing the critical need for healthcare cost containment. With an expansive distribution network spanning 50 countries and reaching two-thirds of the global population, the firm has established a robust market presence that bridges the gap between complex laboratory science and practical bedside application.
How much funding has Critical Diagnostics raised?
Critical Diagnostics has raised a total of $11.1M across 2 funding rounds:
Private Equity
$2.6M
Private Equity
$8.5M
Private Equity (2012): $2.6M, investors not publicly disclosed
Private Equity (2018): $8.5M, investors not publicly disclosed
Key Investors in Critical Diagnostics
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Critical Diagnostics?
With the recent influx of capital, Critical Diagnostics is well-positioned to accelerate its research and development pipeline, focusing on the next generation of diagnostic tools that promise to redefine standard-of-care protocols. The strategic deployment of these funds will likely prioritize the expansion of clinical validation studies and the strengthening of international distribution channels. As the company transitions into this mature phase of enterprise-level growth, the focus will remain on scaling its biomarker platform to meet the rising demand for cost-effective, high-accuracy diagnostic solutions in an increasingly value-based healthcare environment.
See full Critical Diagnostics company page
